Health-care budgets are largely spent on treating the complications of chronic diseases, many of which have preventable risk factors. Here, we discuss some of the key issues in the necessary move towards a 'prevention model' of health care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ross, J. S. et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320–368 (2009).
Yazicki, Y. & Simsek, I. Treatment options for rheumatoid athritis beyond TNF-α inhibitors. Exp. Rev. Clin. Pharm. 3, 663–666 (2010).
Breckenridge, A., Mello, M. & Psaty, B. M. New horizons in pharmaceutical regulation. Nature Rev. Drug Discov. 11, 501–502 (2012).
Acknowledgements
The views expressed are personal and do not necessarily reflect the views of any of the regulatory agencies.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Breckenridge, A., Eichler, HG. Towards a prevention model of health care. Nat Rev Drug Discov 12, 563–564 (2013). https://doi.org/10.1038/nrd4077
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4077
This article is cited by
-
European perspective for effective cancer drug development
Nature Reviews Clinical Oncology (2014)